A2M (academia to market) Pharmaceuticals is a spin-off of Schwarz Pharma developing the Schwarz portfolio following the merger with UCB S.A.. A2M Pharma GmbH has the mission of progressing the most promising of these projects until clinical proof of concept and licensing the remainder at earlier stages. 

A2M Pharma GmbH was founded in December 2009 and is led by an experienced management team. Its business premises are located in Monheim on the former Schwarz Pharma campus.